Chemotherapy-Induced Neoantigen Nanovaccines Enhance Checkpoint Blockade Cancer Immunotherapy
ACS Nano · 10.10.2023 · 17 (19) · 18818-18831
DOI: 10.1021/acsnano.3c03274 ↗Kurz gefasst
Fachartikel in der Zeitschrift ACS Nano, online erschienen am 26.09.2023. Verfasst von Guiyuan Chen und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemistry, University of Science and Technology of China, Hefei 230026, China. Hauptthemen laut MEDLINE: Neoplasms, Antineoplastic Agents, Cancer Vaccines. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 54 Literaturangaben. Gefördert von: University of Science and Technology of China, Fundamental Research Funds for the Central Universities, National Natural Science Foundation of China.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Chemotherapeutics have the potential to increase the efficacy of cancer immunotherapies by stimulating the production of damage-associated molecular patterns (DAMPs) and eliciting mutations that result in the production of neoantigens, thereby increasing the immunogenicity of cancerous lesions. However, the dose-limiting toxicity and limited immunogenicity of chemotherapeutics are not sufficient to induce a robust antitumor response. We hypothesized that cancer cells in vitro treated with ultrahigh doses of various chemotherapeutics artificially increased the abundance, variety, and specificity of DAMPs and neoantigens, thereby improving chemoimmunotherapy. The in vitro chemotherapy-induced (IVCI) nanovaccines manufactured from cell lysates comprised multiple neoantigens and DAMPs, thereby exhibiting comprehensive antigenicity and adjuvanticity. Our IVCI nanovaccines exhibited enhanced immune responses in CT26 tumor-bearing mice, with a significant increase in CD4+/CD8+ T cells in tumors in combination with immune checkpoint inhibitors. The concept of IVCI nanovaccines provides an idea for manufacturing and artificial enhancement of immunogenicity vaccines to improve chemoimmunotherapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Chemistry, University of Science and Technology of China, Hefei 230026, China.
- School of Medicine and Health Sciences, The George Washington University, Washington D.C. 20052, United States.
- Department of Radiation Oncology, University of Texas Southwestern Medical Center at Dallas, Dallas, Texas 75390, United States.
- Hefei National Research Center for Physical Sciences at the Microscale, University of Science and Technology of China, Hefei 230026, China.
- The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei 230026, China.
- CAS Key Lab of Soft Matter Chemistry, University of Science and Technology of China, Hefei 230026, China.
ORCID-Profile: Yuanzeng Min
Förderung
- University of Science and Technology of China
- Fundamental Research Funds for the Central Universities
- National Natural Science Foundation of China
Zitieren
APA
Chen, G., Li, X., Li, R., Wu, K., Lei, Z., Dai, R., Roche, K., Wang, A. Z., & Min, Y. (2023). Chemotherapy-Induced Neoantigen Nanovaccines Enhance Checkpoint Blockade Cancer Immunotherapy. ACS Nano, 17(19), 18818-18831. https://doi.org/10.1021/acsnano.3c03274
Vancouver
Chen G, Li X, Li R, Wu K, Lei Z, Dai R, et al. Chemotherapy-Induced Neoantigen Nanovaccines Enhance Checkpoint Blockade Cancer Immunotherapy. ACS Nano. 2023;17(19):18818-18831. doi:10.1021/acsnano.3c03274
BibTeX
@article{Chen2023,
author = {Chen, Guiyuan and Li, Xiangxia and Li, Rui and Wu, Kecheng and Lei, Zhouhang and Dai, Ruike and Roche, Kyle and Wang, Andrew Z and Min, Yuanzeng},
title = {Chemotherapy-Induced Neoantigen Nanovaccines Enhance Checkpoint Blockade Cancer Immunotherapy},
journal = {ACS Nano},
year = {2023},
volume = {17},
number = {19},
pages = {18818--18831},
doi = {10.1021/acsnano.3c03274}
}
EUVIMED